Quintiles going private
Executive Summary
Quintiles accepts bid from Chairman Dennis Gillings, PhD, to buy company for $14.50/share. Agreement represents $3.25/share increase over Gillings' original proposal (1"The Pink Sheet" Nov. 18, 2002, p. 9)...
You may also be interested in...
Quintiles Rejects Buy-Out Offer From Founder Gillings, Weighs Options
Quintiles will look for potential buyers after rejecting an acquisition offer from founder and Chairman Dennis Gillings, PhD
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.